The Johns Hopkins Alliance for Science & Technology Development ("Alliance") is a 36-member committee charged with evaluating the commercial viability of selected research projects at the Johns Hopkins University. Members of the Alliance evaluates marketing opportunities and provides assistance with the identification of financing to enable the commercialization of worthy discoveries.

The Alliance consists of pharmaceutical and biotech executives, medical device designers and manufacturers, representatives from the diagnostics world and venture capitalists, as well as angel investors.

The Alliance's charter is to evaluate research projects within the University, determine the commercial strength of each project, and assign an Alliance member to champion its development and marketability. The group will also become the university's conduit toward creating awareness among industry leaders and business entrepreneurs.

This alliance among business leaders and university researchers has been made possible under the provisions of the Bayh-Dole Act, which encourages the utilization of inventions produced under federal funding and promotes the participation of universities and small businesses in the development and commercialization process. It also permits exclusive licensing with transfer of an invention to the marketplace.

For more information please contact:
Helen Montag
Corporate Relations Manager
hmontag@jhmi.edu
410-516-4976 or 410-371-8776

The Johns Hopkins University
Alliance for Science and Technology Development
Industry Membership

Aris Melissaratos, Chairman
Senior Advisor to the President for Enterprise Development
Johns Hopkins University

Liza Bailey
Private Investor / retired Credit Suisse Investment Banking Managing Director

James J. Barry, PhD
VP Corp. Research & Advanced Tech. Dev.
--Boston Scientific

David S. Block, MD, MBA
President and CEO
-- Gliknik, Inc.

David S. Bredt, MD, PhD
Vice President, Integrative Biology
--Lilly Research Laboratories; Eli Lilly & Co.

James N. Campbell, MD
Executive in Residence
--Interwest Partners
CEO
--Arcion Therapeutics, Inc.

C. Thomas Caskey, MD, FACP
Director & CEO
--Brown Foundation Institute of Molecular Medicine
Executive Vice President of Molecular Medicine and Genetics
--The University of Texas Health Science Center at Houston

Albert J. Di Rienzo
President & CEO
--Blue Highway, LLC, a WelchAllyn Company

Kenneth Fasman, PhD
Vice President and Chief Technology Officer
--Dr. Miriam and Sheldon G. Adelson Medical Research Foundation

Robert Garland, MD
Partner
--New Enterprise Associates

Philip Goelet, PhD
Director
--Red Abbey

Elizabeth Good
Director, Strategic Investments
--University of Maryland at Baltimore

Steve Gorlin
Principal
--Gorlin Companies

David W. Hockenbrocht
Founding Chair of the Alliance
(retired, President & CEO, Sparton Corporation)

Leroy E. Hood, MD, PhD
President
--Institute for Systems Biology

Linda Jolliffe, PhD
VP, External Research and Early Development
--Johnson & Johnson Pharmaceutical Research & Dev., LLC

Edwin M. Kania, Jr.
Managing Partner and Chairman
--Flagship Ventures

Robert S. King
--FIVE PRIME ADVISORS, LLC

Chris Kroeger, MD, MBA
Principal
--Aurora Funds, Inc.

Joseph Lawler, MD, PhD
--MKM Longboat

Robert D. Mashal, MD
President & CEO
--Alinea Pharmaceuticals

Troy Moore
Chief Technology Officer
--Open Biosystems

James Niedel, MD, PhD
Managing Director
--New Leaf Venture Partners, LLC

Stephen N. Oesterle, MD
Sr. Vice President for Medicine and Technology
--Medtronic, Inc.

John Perchorowicz, PhD
Vice President, Business Development
-- RCT BioVentures/Research Corporation Technologies, Inc.

James A. Poulos, III
VP, Technology Transfer and Commercialization
--Maryland Technology Development Corp. (TEDCO)

Major General Garrison Rapmund, MD, U.S. Army, Retired
Sr. Fellow, Krasnow Institute for Advanced Study, George Mason University

Bruce C. Robertson, PhD
Managing Director
--H.I.G. Ventures

Mark C. Rogers, MD, MBA
Chairman and CEO
--Bradmer Pharmaceuticals

Robert T. Sarisky, PhD, MBA
VP, External Research and Early Development
--Johnson & Johnson Pharmaceutical Research & Dev., LLC

Thomas C. Seoh

Christopher Shen, MD, MBA
Principal
--Essex Woodlands Health Ventures

Irving Sherman, MD
(retired neurosurgeon)

Amita Shukla
Principal
--New Enterprise Associates

Craig R. Smith, MD
--Williston Consulting, LLC
(retired Chair, President, & CEO, Guilford Pharmaceuticals)

Joseph M. Smith, MD, PhD, FACC
VP, Emerging Technologies, Corporate Office of Science and Technology
--Johnson & Johnson

Jason Sydow, PhD
Principal
--Questmark Partners